The cost-effectiveness of long-term post-treatment peer recovery support services in the United States

被引:0
|
作者
de Martell, Sierra Castedo [1 ,2 ]
Moore, Margaret Brannon [2 ]
Wang, Hannah [2 ]
Steiker, Lori Holleran
Wilkerson, J. Michael [2 ]
Ranjit, Nalini [2 ]
Mccurdy, Sheryl A. [2 ]
Brown, H. Shelton [2 ]
机构
[1] Lighthouse Inst, Chestnut Hlth Syst, Bloomington, IL USA
[2] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA
基金
美国国家卫生研究院;
关键词
Peer recovery support services; cost-effectiveness analysis; cost-effectiveness calculator; recovery community organizations; recovery community centers; peer coaching; SUBSTANCE-ABUSE TREATMENT; HEALTH;
D O I
10.1080/00952990.2024.2406251
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Peer recovery support services (PRSS) have been widely adopted across a variety of settings, but little is known about their economic impact.Objectives: To conduct a cost-effectiveness analysis of long-term, PRSS delivered after specialty substance use disorder (SUD) treatment (post-treatment), and to describe the development of a free, web-based cost-effectiveness calculator based on this analysis.Methods: Using publicly available data from a variety of sources, post-treatment PRSS were compared to specialty SUD treatment from the societal (broad perspective including costs like participant time) and health systems perspectives (only costs borne by health system), and in terms of quality-adjusted life years (QALYs) added and people in recovery. Whenever possible, 2019 data were used to avoid the impacts of COVID-19. Standard willingness-to-pay thresholds and additional treatment episode cost ($17,203.74) were used. One-way and probabilistic sensitivity analyses were conducted. Two recovery community organizations (RCOs) were involved in model refinement and calculator development in 2022.Results: Post-treatment PRSS were cost-effective to all thresholds and perspectives: $5,898.60 per QALY and $10,562.08 per person in recovery from the health system perspective, and $3,421.58 per QALY and $6,126.72 per person in recovery from the societal perspective, and post-treatment PRSS remained cost-effective across a variety of conditions in the sensitivity analyses. A cost-effectiveness calculator was developed from the analysis and is available at https://go.uth.edu/cea.Conclusions: In light of finding PRSS cost-effective, the expansion of PRSS across the US should continue, and may be aided by using the cost-effectiveness calculator to estimate tailored results for a specific program.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension
    van Gestel, Aukje
    Schouten, Jan S. A. G.
    Beckers, Henny J. M.
    Severens, Johan L.
    Hendrikse, Fred
    Webers, Carroll A. B.
    ACTA OPHTHALMOLOGICA, 2014, 92 (06) : 513 - 523
  • [32] The cost-effectiveness of noninstitutional long-term care services: Review and synthesis of the most recent evidence
    Grabowski, DC
    MEDICAL CARE RESEARCH AND REVIEW, 2006, 63 (01) : 3 - 28
  • [33] Cost-effectiveness of long-term treatment of hypertension with irbesartan vs. losartan or no treatment in Denmark
    Knudsen, M. S.
    Lange, M.
    Dahl, E.
    VALUE IN HEALTH, 2006, 9 (06) : A348 - A348
  • [34] Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States
    Valentine, William J.
    Hoog, Meredith
    Mody, Reema
    Belger, Mark
    Pollock, Richard
    DIABETES OBESITY & METABOLISM, 2023, 25 (05): : 1292 - 1300
  • [35] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Lin, Liang
    Teng, Monica
    Zhao, Ying Jiao
    Khoo, Ai Leng
    Seet, Raymond Chee Seong
    Yong, Quek Wei
    Yeo, Tiong Cheng
    Lim, Boon Peng
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 187 - 197
  • [36] A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
    Tarride, Jean-Eric
    Hopkins, Robert
    Blackhouse, Gord
    Bowen, James M.
    Bischof, Matthias
    Von Keyserlingk, Camilla
    O'Reilly, Daria
    Xie, Feng
    Goeree, Ron
    PHARMACOECONOMICS, 2010, 28 (04) : 255 - 277
  • [37] Long-term cost-effectiveness analysis of sacral neuromodulation in the treatment of severe faecal incontinence
    Valencia, Mario de Miguel J.
    Hita, Juan Cabases M.
    Iriso, Eduardo Sanchez
    Martinez, Fabiola Oteiza
    Ibanez, Inaki Alberdi
    Lopez, Alfonso Alvarez
    Hurtado, Hector Ortiz
    Velasco, Mario J. de Miguel J.
    COLORECTAL DISEASE, 2023, 25 (09) : 1821 - 1831
  • [38] A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
    Jean-Eric Tarride
    Robert Hopkins
    Gord Blackhouse
    James M. Bowen
    Matthias Bischof
    Camilla Von Keyserlingk
    Daria O’Reilly
    Feng Xie
    Ron Goeree
    PharmacoEconomics, 2010, 28 : 255 - 277
  • [39] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Liang Lin
    Monica Teng
    Ying Jiao Zhao
    Ai Leng Khoo
    Raymond Chee Seong Seet
    Quek Wei Yong
    Tiong Cheng Yeo
    Boon Peng Lim
    Cardiovascular Drugs and Therapy, 2015, 29 : 187 - 197
  • [40] A COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE APPROACHES FOR LONG-TERM TREATMENT OF PROXIMAL VENOUS THROMBOSIS
    HULL, R
    RASKOB, G
    HIRSH, J
    THROMBOSIS AND HAEMOSTASIS, 1983, 50 (01) : 66 - 66